Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
OM Stock Summary
Top 10 Correlated ETFs
OM
In the News
Outset Medical, Inc. (OM) Q4 2023 Earnings Call Transcript
Outset Medical, Inc. (OM) Q4 2023 Earnings Call Transcript
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?
Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical to Report Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, February 21, 2024
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2023 after the close of trading on Wednesday, February 21, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief F.
Outset Medical to Present at BofA Home Care Conference
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a virtual panel discussion at the BofA Securities Home Care Conference on Monday, December 4, 2023, at 12:00pm PT / 3:00pm ET. The panel discussion will include Leslie Trigg, Outset's Chair and Chief Executive Officer, Michael Aragon, MD.
5 Struggling Stocks to Buy at a Discount
These five companies have glimmers of hope that the market has yet to fully recognize. Each is trading at a significant discount to recent highs.
2 of the Cheapest Stocks I Own
Target has moved past its inventory woes and is showing positive signs. Outset Medical has faced setbacks, but still has a long runway for growth.
After Plunging -62.36% in 4 Weeks, Here's Why the Trend Might Reverse for Outset Medical, Inc. (OM)
Outset Medical, Inc. (OM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -68.16% in 4 Weeks, Here's Why You Should You Buy the Dip in Outset Medical, Inc. (OM)
The heavy selling pressure might have exhausted for Outset Medical, Inc. (OM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Outset Medical analysts slash price objective after multiple missteps
Outset Medical Inc stock was downgraded by BofA Securities analysts to ‘Underperform' from ‘Buy', and its price objective was cut to $3 per share from $32, after the medical technology company reported lower-than-expected preliminary third-quarter 2023 revenue and warned of reduced capital spending in 4Q. "We think the Underperform rating is appropriate as Outset has had multiple execution missteps now and companies without profitability have even less margin of error given there is no real profitability valuation floor," the analysts wrote.
Outset Medical stock plunges on revenue hit from FDA warning letter
Outset Medical Inc shares sank as much as 40% in pre-market trading on Friday after the medical technology company reported lower-than-expected preliminary third-quarter 2023 revenue of $30.4 million and warned of reduced capital spending in 4Q. Outset also said it now expects revenue for 2023 to be about $130 million, down from the company's previous forecast of $144 million to $150 million in August.
OM Financial details
OM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.5 | 3.05 | 2.25 | 2.4 | 2.63 | |
Net income per share | -2.27 | -7.38 | -2.89 | -3.38 | -3.48 | |
Operating cash flow per share | -2.34 | -6.05 | -2.86 | -3.03 | -2.65 | |
Free cash flow per share | -2.45 | -6.61 | -2.93 | -3.2 | -2.72 | |
Cash per share | 2.33 | 19.25 | 7.45 | 5.97 | 4.1 | |
Book value per share | -12.37 | 20.09 | 8.21 | 5.11 | 2.48 | |
Tangible book value per share | -12.37 | 20.09 | 8.21 | 5.11 | 2.48 | |
Share holders equity per share | -12.37 | 20.09 | 8.21 | 5.11 | 2.48 | |
Interest debt per share | 1.11 | 2.5 | 0.87 | 2.22 | 3 | |
Market cap | 1.83B | 929.79M | 2.1B | 1.24B | 268.27M | |
Enterprise value | 1.82B | 673.42M | 1.96B | 1.27B | 335.95M | |
P/E ratio | -26.73 | -7.7 | -15.93 | -7.63 | -1.55 | |
Price to sales ratio | 121.06 | 18.62 | 20.48 | 10.78 | 2.06 | |
POCF ratio | -25.97 | -9.39 | -16.13 | -8.53 | -2.04 | |
PFCF ratio | -24.81 | -8.6 | -15.75 | -8.07 | -1.99 | |
P/B Ratio | -4.9 | 2.83 | 5.62 | 5.06 | 2.18 | |
PTB ratio | -4.9 | 2.83 | 5.62 | 5.06 | 2.18 | |
EV to sales | 120.54 | 13.49 | 19.07 | 11.04 | 2.58 | |
Enterprise value over EBITDA | -27.59 | -5.73 | -15.05 | -8.07 | -2.18 | |
EV to operating cash flow | -25.86 | -6.8 | -15.02 | -8.74 | -2.56 | |
EV to free cash flow | -24.7 | -6.23 | -14.67 | -8.27 | -2.49 | |
Earnings yield | -0.04 | -0.13 | -0.06 | -0.13 | -0.64 | |
Free cash flow yield | -0.04 | -0.12 | -0.06 | -0.12 | -0.5 | |
Debt to equity | -0.08 | 0.12 | 0.1 | 0.42 | 1.11 | |
Debt to assets | 0.33 | 0.1 | 0.08 | 0.26 | 0.43 | |
Net debt to EBITDA | 0.12 | 2.18 | 1.11 | -0.19 | -0.44 | |
Current ratio | 3.2 | 9.43 | 7.93 | 7.19 | 5.26 | |
Interest coverage | -16.52 | -49.67 | -76.1 | -45.15 | -13.39 | |
Income quality | 1.03 | 0.81 | 0.99 | 0.89 | 0.76 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.59 | 0.61 | 0.35 | 0.35 | 0.35 | |
Research and developement to revenue | 1.55 | 0.58 | 0.36 | 0.42 | 0.44 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0.09 | 0.02 | 0.06 | 0.03 | |
Capex to revenue | -0.22 | -0.18 | -0.03 | -0.07 | -0.03 | |
Capex to depreciation | -1.7 | -2.88 | -0.6 | -1.61 | -0.59 | |
Stock based compensation to revenue | 0.06 | 0.43 | 0.17 | 0.24 | 0.3 | |
Graham number | 25.14 | 57.75 | 23.12 | 19.72 | 13.94 | |
ROIC | 0.2 | -0.31 | -0.31 | -0.45 | -0.64 | |
Return on tangible assets | -0.77 | -0.3 | -0.28 | -0.41 | -0.55 | |
Graham Net | -12.81 | 15.51 | 6.34 | 3.74 | 1.25 | |
Working capital | 54.74M | 309.22M | 358.11M | 321.7M | 235.9M | |
Tangible asset value | -372.19M | 328.61M | 374.08M | 245.99M | 122.89M | |
Net current asset value | -380.91M | 270.69M | 320.42M | 219.52M | 100.3M | |
Invested capital | -0.08 | 0.12 | 0.1 | 0.42 | 1.11 | |
Average receivables | 2.5M | 5.19M | 16.03M | 26.84M | 30.53M | |
Average payables | 4.17M | 4.95M | 3.36M | 1.18M | 3.22M | |
Average inventory | 3.81M | 11.49M | 28.78M | 45.33M | 50.35M | |
Days sales outstanding | 94.75 | 47.28 | 91.07 | 88.8 | 92.33 | |
Days payables outstanding | 55.06 | 28.68 | 6.77 | 2.26 | 20.98 | |
Days of inventory on hand | 51.02 | 106.56 | 150.56 | 192.62 | 177.2 | |
Receivables turnover | 3.85 | 7.72 | 4.01 | 4.11 | 3.95 | |
Payables turnover | 6.63 | 12.73 | 53.88 | 161.76 | 17.4 | |
Inventory turnover | 7.15 | 3.43 | 2.42 | 1.89 | 2.06 | |
ROE | 0.18 | -0.37 | -0.35 | -0.66 | -1.41 | |
Capex per share | -0.11 | -0.56 | -0.07 | -0.17 | -0.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.66 | 0.69 | 0.74 | 0.61 | 0.61 | |
Net income per share | -0.86 | -0.9 | -0.9 | -0.93 | -0.77 | |
Operating cash flow per share | -0.71 | -0.92 | -0.58 | -0.68 | -0.49 | |
Free cash flow per share | -0.76 | -0.93 | -0.59 | -0.7 | -0.51 | |
Cash per share | 5.94 | 5.11 | 4.55 | 3.89 | 4.05 | |
Book value per share | 5.09 | 4.43 | 3.74 | 3.05 | 2.45 | |
Tangible book value per share | 5.09 | 4.43 | 3.74 | 3.05 | 2.45 | |
Share holders equity per share | 5.09 | 4.43 | 3.74 | 3.05 | 2.45 | |
Interest debt per share | 2.18 | 2.17 | 2.18 | 2.13 | 2.78 | |
Market cap | 1.25B | 897.61M | 1.07B | 543.05M | 271.87M | |
Enterprise value | 1.28B | 964.28M | 1.14B | 609.99M | 339.55M | |
P/E ratio | -7.53 | -5.1 | -6.08 | -2.94 | -1.76 | |
Price to sales ratio | 39.01 | 26.82 | 29.7 | 17.89 | 8.91 | |
POCF ratio | -36.19 | -20.06 | -37.99 | -15.97 | -11.12 | |
PFCF ratio | -34.1 | -19.7 | -36.94 | -15.61 | -10.66 | |
P/B Ratio | 5.08 | 4.15 | 5.85 | 3.57 | 2.21 | |
PTB ratio | 5.08 | 4.15 | 5.85 | 3.57 | 2.21 | |
EV to sales | 39.95 | 28.81 | 31.56 | 20.09 | 11.13 | |
Enterprise value over EBITDA | -33.72 | -23.61 | -27.87 | -14.23 | -10.1 | |
EV to operating cash flow | -37.06 | -21.55 | -40.37 | -17.94 | -13.89 | |
EV to free cash flow | -34.92 | -21.16 | -39.26 | -17.54 | -13.32 | |
Earnings yield | -0.03 | -0.05 | -0.04 | -0.09 | -0.14 | |
Free cash flow yield | -0.03 | -0.05 | -0.03 | -0.06 | -0.09 | |
Debt to equity | 0.42 | 0.48 | 0.56 | 0.68 | 1.11 | |
Debt to assets | 0.26 | 0.28 | 0.31 | 0.34 | 0.43 | |
Net debt to EBITDA | -0.79 | -1.63 | -1.64 | -1.56 | -2.01 | |
Current ratio | 7.19 | 7.62 | 6.34 | 5.35 | 5.26 | |
Interest coverage | -19 | -14.78 | -14.01 | -14.15 | -10.93 | |
Income quality | 0.83 | 49.73K | 0.64 | 36.56K | 0.63 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.31 | 0.35 | 0.31 | 0.39 | 0.34 | |
Research and developement to revenue | 0.36 | 0.41 | 0.41 | 0.53 | 0.41 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.06 | 0.02 | 0.03 | 0.02 | 0.04 | |
Capex to revenue | -0.07 | -0.02 | -0.02 | -0.03 | -0.03 | |
Capex to depreciation | -1.66 | 4.88 | -0.53 | -0.53 | -0.73 | |
Stock based compensation to revenue | 0.23 | 0 | 0.28 | 0 | 0.3 | |
Graham number | 9.9 | 9.48 | 8.7 | 7.96 | 6.5 | |
ROIC | -0.11 | -0.13 | -0.15 | -0.17 | -0.14 | |
Return on tangible assets | -0.1 | -0.12 | -0.13 | -0.15 | -0.12 | |
Graham Net | 3.73 | 3.12 | 2.48 | 1.79 | 1.23 | |
Working capital | 321.7M | 293.01M | 260.58M | 230.75M | 235.9M | |
Tangible asset value | 245.99M | 216.29M | 183.11M | 152.06M | 122.89M | |
Net current asset value | 219.52M | 190.9M | 158.07M | 128.29M | 100.3M | |
Invested capital | 0.42 | 0.48 | 0.56 | 0.68 | 1.11 | |
Average receivables | 25.29M | 31.19M | 35.61M | 36.2M | 34.24M | |
Average payables | 1.02M | 1.3M | 2.1M | 2.55M | 4.35M | |
Average inventory | 53.37M | 49.6M | 46.11M | 46.38M | 48.74M | |
Days sales outstanding | 78.93 | 92.28 | 92.15 | 105.21 | 97.3 | |
Days payables outstanding | 2.03 | 6.62 | 7.04 | 11.17 | 23.01 | |
Days of inventory on hand | 173.29 | 158.88 | 141.32 | 187.16 | 194.31 | |
Receivables turnover | 1.14 | 0.98 | 0.98 | 0.86 | 0.93 | |
Payables turnover | 44.33 | 13.6 | 12.78 | 8.06 | 3.91 | |
Inventory turnover | 0.52 | 0.57 | 0.64 | 0.48 | 0.46 | |
ROE | -0.17 | -0.2 | -0.24 | -0.3 | -0.31 | |
Capex per share | -0.04 | -0.02 | -0.02 | -0.02 | -0.02 |
OM Frequently Asked Questions
What is Outset Medical, Inc. stock symbol ?
Outset Medical, Inc. is a US stock , located in San jose of Ca and trading under the symbol OM
Is Outset Medical, Inc. buy or a sell ?
4 stock analysts have 4 predictions with a medium analyst target price of $27.75. The lowest prediction is $23 and the highest is $34
What is OM stock prediction ?
What is Outset Medical, Inc. stock quote today ?
Outset Medical, Inc. stock price is $2.315 today.
Is Outset Medical, Inc. stock public?
Yes, Outset Medical, Inc. is a publicly traded company.